NCT03821077

Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma

Prospective Observational Study to Evaluate the Efficacy and Safety of Treatment With "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Associated Asthma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 122 (actual)
• Sponsor: Roxall Medicina España S.A · Industry
• Sex: All
• Age: 5 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixture of 2 allergenic extracts (pollens or mites), in polymerized-depot formulation, administered in its different available allergenic extracts mixtures (2 pollens or 2 mites), and in one of the 2 recommended administration schedules (1 Day or Rapid).

Conditions

• Rhinitis, Allergic
• Rhinoconjunctivitis

Interventions

Type	Name	Description
BIOLOGICAL	Allergen Immunotherapy (AIT)	Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation

Timeline

• Start date: 2018-08-30
• Primary completion: 2021-09-13
• Completion: 2021-09-13
• First posted: 2019-01-29
• Last updated: 2021-10-20

Locations

10 sites across 1 country: Spain